ISRCTN14033813进行中（未招募）未知
Establishing a single-sex controlled human Schistosoma mansoni infection model for Uganda: safety and dose finding
ondon School of Hygiene & Tropical Medicine0 个研究点目标入组 66 人开始时间: 2021年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 66
研究概览
简要总结
2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37538934/ (added 04/08/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Volunteer is aged =18 and =45 years and in good health
- •2. Volunteer is able to communicate well with the research team members and is available to attend all study visits
- •3. Volunteer has an adequate understanding of the procedures of the study and agrees to abide strictly thereby
- •4. Volunteer will remain within Uganda during the study period and is reachable by mobile telephone from until at least week 16 of the study period
- •5. Volunteer understands the need to avoid contact with waterbodies where Schistosoma is transmitted and can demonstrate that they are able and willing to do so for the full 12-16 week period until the controlled infection has been cured
- •6. Volunteer agrees to refrain from blood donation throughout the study period
- •7. For a female volunteer: volunteer agrees to use adequate contraception and not to breastfeed for the duration of the study
- •8. Volunteer has signed informed consent
排除标准
- •1. Evidence of current Schistosoma infection based on highly sensitive CAA assay (at a conservative cut-off level of >0.5 pg/ml)
- •2. Evidence of malaria or of intestinal helminth infections (if identified, these will be treated and the volunteer may be reconsidered for inclusion)
- •3. Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, haematological, infectious, immune-deficient, psychiatric and other disorders, which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results. These include, but are not limited to, any of the following. Note that volunteers may be reconsidered for inclusion following recovery from treatable conditions:
- •3.1. Temperature =37.5°C/99.5°F
- •3.2. Body weight <50 kg or Body Mass Index (BMI) <18.0 or >30.0 kg/m² at screening
- •3.3. Positive HIV, HBV or HCV screening tests
- •3.4. The use of immune modifying drugs within three months prior to study onset (inhaled and topical corticosteroids and oral anti-histamines exempted) or expected use of such during the study period
- •3.5. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years
- •3.6. Any history of treatment for severe psychiatric disease by a psychiatrist in the past year
- •3.7. History of drug or alcohol abuse interfering with normal social function in the period of 1 year prior to study onset
- •3.8. Any clinically significant abnormalities (including extended QT interval) on electrocardiogram
- •4. The chronic use of any drug known to interact with praziquantel, artesunate or lumefantrine metabolism (e.g. phenytoïn, carbamazepine, phenobarbital, primidone, dexamethasone, rifampicin, cimetidine, flecainide, metoprolol, imipramine, amitriptyline, clomipramine, class IA and III antiarrhythmics, antipsychotics, antidepressants, macrolides, fluoroquinolones, imidazole- and triazole antimycotics, antihistamines). Because lumefantrine may cause extension of QT-time, chronic use of drugs with effect on QT interval are excluded from the study
- •5. For female volunteers: positive urine pregnancy test at screening, or breastfeeding
- •6. Known hypersensitivity to or contra-indications (including co-medication) for use of praziquantel, artesunate or lumefantrine
- •7. Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period
- •8. Being an employee or student of the Uganda Virus Research Institute or its campus partners, or of Entebbe Hospital
- •9. Volunteer who, in the opinion of the investigator, does not fully understand the purpose of the study or requirements for participation or is unlikely to adhere to the requirements of the study
研究者
相似试验
已完成
不适用
Establishing a Single-sex Controlled Human Schistosoma mansoni Infection Model: safety and dose finding10019381SchistosomiasisbilharziaNL-OMON46890eids Universitair Medisch Centrum17
已完成
不适用
Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose FindingSchistosoma MansoniSchistosomiasisNCT02755324Leiden University17
已完成
1 期
Clinical trial to assess the safety of a coronavirus vaccine in healthy men and womeCOVID-19 (SARS-CoV-2 infection)Infections and InfestationsISRCTN17072692Imperial College London192
已完成
不适用
Single-sex Female Controlled Human Schistosomiasis Mansoni InfectionSchistosomiasisSchistosomiasis MansoniNCT04269915Leiden University Medical Center13
进行中（未招募）
不适用
Surgical treatment of osteoporotic hip fracturesInterthcohanteric hip fractures in the elderlyInjury, Occupational Diseases, PoisoningFracture of neck of femurISRCTN15588442General University Hospital of Patras200